Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced <i>EGFR</i>-Mutated Non-small Cell Lung Cancer: A Meta-Analysis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.